MTNB vs. TRIB, COCP, RLYB, ERNA, ABP, EDSA, MBRX, UBX, MEIP, and UPXI
Should you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Trinity Biotech (TRIB), Cocrystal Pharma (COCP), Rallybio (RLYB), Eterna Therapeutics (ERNA), Abpro (ABP), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Unity Biotechnology (UBX), MEI Pharma (MEIP), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.
Matinas Biopharma vs.
Trinity Biotech (NASDAQ:TRIB) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, community ranking, institutional ownership and dividends.
Trinity Biotech received 335 more outperform votes than Matinas Biopharma when rated by MarketBeat users.
Trinity Biotech has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Matinas Biopharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Matinas Biopharma's return on equity.
79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 4.6% of Matinas Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Trinity Biotech had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 2 mentions for Trinity Biotech and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 beat Trinity Biotech's score of -0.37 indicating that Matinas Biopharma is being referred to more favorably in the news media.
Matinas Biopharma has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Trinity Biotech beats Matinas Biopharma on 8 of the 15 factors compared between the two stocks.
Get Matinas Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Matinas Biopharma Competitors List
Related Companies and Tools
This page (NYSE:MTNB) was last updated on 5/28/2025 by MarketBeat.com Staff
